Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy

Completed · Not applicable

Conditions studied: Doxorubicin Induced Cardiomyopathy, Breast Cancer, Gastric Cancer, Leukemia

In brief

The purpose of this study is to identify patients at risk for future heart failure using novel markers of early cardiac damage and determine if exercise training can improve these emerging markers as well as overall fitness and quality of life.

Key facts

Study ID

NCT02796365

Run by

Henry Ford Health System

People needed

29

Starts

2016-06-01

Expected to finish

2018-12-01

Last updated by the study team

2018-12-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with cancer who are undergoing or have completed the chemotherapy drugs doxorubicin and/or trastuzumab.
• Have had a recent echocardiogram with a relative reduction in LV strain of >10%.
• If no recent echocardiogram, have a troponin value >0.04 ng/mL, or an increase of 0.04 ng/mL if baseline troponin is elevated.
• Age >/= 18 years.
• Eastern Cooperative Oncology Group (ECOG) scale 0-2.
• Males and females.

You may not qualify if…

• Patients with an Ejection Fraction <50%
• Patients not deemed appropriate by a cardiologist or oncologist
• Patients with an ECOG scale >2
• Inability to perform exercise
• Patients who already report exercising >2days per week for >29 minutes

Where it is running

• William Clay Ford Center for Athletic Medicine — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.